Deep Blue Medical Advances, Inc. | $5,600,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)
Ideally | $10,000,000 | (Apr 22, 2026)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Monk | $25,000,000 | (Apr 22, 2026)
Reliable Robotics Corporation | $160,000,000 | (Apr 22, 2026)
Humble Robotics | $24,000,000 | (Apr 22, 2026)
Sinai.ai | $1,450,000 | (Apr 22, 2026)
Qualitate | $7,000,000 | (Apr 22, 2026)
Exergy3 Limited | $13,523,900 | (Apr 22, 2026)
Syenta | $26,000,000 | (Apr 22, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)